18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma

Recruiting now · Phase 2

Conditions studied: Nasopharyngeal Carcinoma

In brief

The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.

Key facts

Study ID

NCT04813705

Run by

Taizhou Hospital

People needed

93

Starts

2022-01-01

Expected to finish

2029-06-30

Last updated by the study team

2023-02-21

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pathology confirmed nasopharyngeal squamous cell carcinoma.
• Stage I-IVA（8thAJCC/UICC staging system).
• Aged 18-80 years.
• KPS≥70.
• Have measurable lesions on 18F-FDG PET/CT before treatment.
• HGB≥90 g/L，ANC≥1.5×109 /L，PLT≥80×109 /L.
• ALT,AST<2.5 fold of ULN；TBIL<2.0×ULN.
• CCR≥60ml/min or Cr<1.5×ULN.
• Signed informed consent.
• Have follow up condition.

You may not qualify if…

• Past malignancies history (except for stage I non-melanoma skin cancer or cervical carcinoma in situ).
• Age <18 or >80years.
• Pregnancy or lactation.
• History of previous radiotherapy (except for non-melanomatous skin cancers outside intended RT treatment volume).
• Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.
• With sever infection and internal disease.
• Major organ dysfunction, such as decompensated cardiopulmonary, kidney, liver failure, cannot tolerate surgical treatment.

Where it is running

• Taizhou Central Hospital — Taizhou, Zhejiang, China (enrolling)
• Taizhou Hospital — Taizhou, Zhejiang, China (enrolling)
• Taizhou Cancer Hospital — Taizhou, Zhejiang, China (enrolling)
• Taizhou Enze Medical Center(Group) Enze Hospital — Taizhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.